Diabetes Mellitus Clinical Trial
— DM-COVEROfficial title:
Comparison of Diabetes Mellitus and Non-diabetes Mellitus Patients for Surface Coverage After Two Types of Drug-eluting Stent Implantation (A Pilot Study)
Diabetic patients are prone to a diffuse and rapidly progressive form of atherosclerosis.
Both clinical and angiographic outcomes following percutaneous coronary intervention (PCI)
are poor in patients with DM compared with those without DM. Autopsy study has shown delayed
neointimal healing with inadequate endothelialization and persistent stent surface fibrin
deposition after DES implantation in DM patients. This might partially contribute to the
high risk of late stent thrombosis.
YINYI Polymer-Free paclitaxel stent is a domestic new type stent with bare metal base with
micro porous surface. However, limited data is available in vivo about the surface coverage
after stent implantation in DM patients because of lack of sensitive imaging modalities.
Optical coherence tomography (OCT) is an optical analogue of intravascular
ultrasound(IVUS)that allows high-resolution tomographic intravascular imaging. Furthermore,
several studies have demonstrated the feasibility of OCT to quantitatively evaluate the
surface coverage and stent conditions in the follow up after PCI .
Therefore, the aim of this study was to analyze the surface coverage and late malapposition
after two types of DES implantation in DM patients compared with non-DM patients by using
OCT and IVUS.
| Status | Recruiting |
| Enrollment | 70 |
| Est. completion date | June 2011 |
| Est. primary completion date | December 2010 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: General Inclusion Criteria: 1. Age : 18-75Y 2. Patients diagnosed as type 2 DM or non-DM. Angiographic Inclusion Criteria: 1. Patients were considered eligible if they have two significant (>70%) angiographic stenosis lesions in different native coronary vessels by CAG. 2. Each target is de novo lesion that can be treated with 1-2 stents. 3. Reference vessel diameter of 2.5 to 4.0 mm. Exclusion Criteria: General Exclusion Criteria: 1. ST-segment elevation myocardial infarction within 7 days prior to the index procedure. 2. Life expectancy <12 months due to another medical condition. 3. Contraindication to antiplatelet therapy or a history of hypersensitivity to sirolimus and paclitaxel or structurally related compounds. 4. Creatinine level more than 2.0mg/dL or ESRD. 5. Severe hepatic dysfunction (more than 3 times normal reference values). 6. Planned surgery procedure=12 months post-index procedure. 7. Known allergy to stainless steel. 8. Female of childbearing potential with a positive pregnancy test within 7 days before the index procedure, or lactating, or intends to become pregnant during the 12 months post index procedure. 9. Patient is not clinically appropriate for OCT evaluation in the opinion of investigator. Angiographic Exclusion Criteria: 1. Study lesion is ostial in location (within 3.0 mm of vessel origin). 2. Study lesion involving arterial segments with highly tortuous anatomy. 3. Complex lesion morphologies (bifurcation needs two stents technique, left main lesion, chronic obstructive occlusion, severe thrombus, heavy calcification). |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| China | The second Affiliated Hospital of Harbin Medical University | Harbin | Heilong jiang |
| Lead Sponsor | Collaborator |
|---|---|
| Harbin Medical University |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Comparison of the surface coverage between DM and Non-DM at 6 months after Cypher and YINYI stent implantation using OCT. | 6-month | Yes | |
| Secondary | Comparison of troponin-I levels between DM and Non-DM at baseline, 8 hours, 16 hours and 24 hours after stent implantation | at every 8-hour in first 24-hour after stent implantation | Yes | |
| Secondary | Comparison of hsCRP concentration between DM and Non-DM at baseline, 8 hours, 16 hours and 24 hours after stent implantation | at every 8-hour in first 24-hour after stent implantation | Yes | |
| Secondary | Comparison of the malapposition, neointimal heterogeneity and the incidence of thrombosis between DM and Non-DM patients after Cypher and YINYI implantation using OCT | 6-month | Yes | |
| Secondary | Comparison of surface coverage, late stent malapposition, neointimal heterogeneity and the incidence of thrombosis between Cypher and YINYI in DM after stenting using OCT | 6-month | Yes | |
| Secondary | Comparison of surface coverage, late stent malapposition, neointimal heterogeneity, and the incidence of thrombosis between Cypher and YINYI in Non-DM after stenting using OCT | 6-month | Yes | |
| Secondary | QCA parameters and IVUS parameters for binary restenosis, late lumen loss. | 6-month | Yes | |
| Secondary | Comparison of the surface coverage, late stent malapposition, neointimal heterogeneity, and the incidence of thrombosis between DM and Non-DM patients after Cypher and YINYI implantation using OCT | 12-month | Yes | |
| Secondary | Comparison of surface coverage, late stent malapposition, neointimal heterogeneity, and the incidence of thrombosis between Cypher and YINYI in DM after stenting using OCT | 12-month | Yes | |
| Secondary | Comparison of surface coverage, late stent malapposition, neointimal heterogeneity, and the incidence of thrombosis between Cypher and YINYI in Non-DM after stenting using OCT | 12-month | Yes | |
| Secondary | QCA parameters and IVUS parameters for binary restenosis, late lumen loss. | 12-month | Yes | |
| Secondary | TLR/TVR | 12-month | Yes | |
| Secondary | MACE | 12-month | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03743779 -
Mastering Diabetes Pilot Study
|
||
| Completed |
NCT03786978 -
Pharmaceutical Care in the Reduction of Readmission Rates in Diabetes Melitus
|
N/A | |
| Completed |
NCT01804803 -
DIgital Assisted MONitoring for DiabeteS - I
|
N/A | |
| Completed |
NCT05039970 -
A Real-World Study of a Mobile Device-based Serious Health Game on Session Attendance in the National Diabetes Prevention Program
|
N/A | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04068272 -
Safety of Bosentan in Type II Diabetic Patients
|
Phase 1 | |
| Completed |
NCT03243383 -
Readmission Prevention Pilot Trial in Diabetes Patients
|
N/A | |
| Completed |
NCT03730480 -
User Performance of the CONTOUR NEXT and CONTOUR TV3 Blood Glucose Monitoring System (BGMS)
|
N/A | |
| Recruiting |
NCT02690467 -
Efficacy, Safety and Acceptability of the New Pen Needle 34gx3,5mm.
|
N/A | |
| Completed |
NCT02229383 -
Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus
|
Phase 3 | |
| Completed |
NCT06181721 -
Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT04489043 -
Exercise, Prediabetes and Diabetes After Renal Transplantation.
|
N/A | |
| Withdrawn |
NCT03319784 -
Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients
|
Phase 4 | |
| Completed |
NCT03542084 -
Endocrinology Auto-Triggered e-Consults
|
N/A | |
| Completed |
NCT02229396 -
Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo
|
Phase 3 | |
| Recruiting |
NCT05544266 -
Rare and Atypical Diabetes Network
|
||
| Completed |
NCT01892319 -
An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy Registry
|
||
| Completed |
NCT05031000 -
Blood Glucose Monitoring Systems: Discounter Versus Brand
|
N/A | |
| Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A |